Lung Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed with small cell lung cancer, confirmed through laboratory testing of tissue samples
• The diagnosis must have been made using a surgical biopsy or core needle biopsy (a fine needle sample may be considered with special approval from the trial's medical overseer)
• People who are able to provide a tumour tissue sample as required by the trial (the timing and type of sample depends on which stage of treatment a person is entering the trial)
• People who are reasonably well and able to carry out daily activities, based on a standard medical fitness scale scored 0 to 2 (confirm with trial site)
• People entering the trial before starting their first treatment must be planning to receive a standard chemotherapy combination of etoposide plus a platinum-based drug, together with an immune therapy drug (atezolizumab or durvalumab)
• People entering the trial after completing first-line treatment must have finished that standard chemotherapy-plus-immunotherapy course, with or without ongoing maintenance therapy
• People whose cancer is classified as "extensive stage," meaning it has spread significantly or cannot be safely treated with radiation alone, based on standard medical guidelines
• People who are willing and able to give their informed consent to participate
• People who have had palliative radiotherapy (radiation to relieve symptoms) may still be eligible, as long as there is at least one area of measurable disease outside the area that was treated with radiation

Who may not be able to join:

• People who have had a second, separate cancer that was diagnosed less than 3 years before the current lung cancer diagnosis, or where treatment for that other cancer finished less than 3 years before the lung cancer diagnosis — with some exceptions for certain low-risk skin cancers (confirm with trial site for details)
• People whose cancer is a mix of small cell and another type of lung cancer
• People whose small cell cancer started in a different organ, or where the cancer may have spread to the lung from somewhere else
• People diagnosed with a related but different type of cancer called large cell neuroendocrine cancer
• People diagnosed with carcinoid or atypical carcinoid tumours
• People whose small cell lung cancer developed as a result of targeted therapy previously used to treat a different type of lung cancer (non-small cell lung cancer)
• People who have previously been treated with a non-standard immunotherapy drug (other than PD-1 or PD-L1 inhibitor types) as part of another trial or study
• People who are not willing to have additional blood samples taken during the trial

Important: Always verify eligibility with the trial site directly before applying.